366 reports of this reaction
1.6% of all BASILIXIMAB reports
#19 most reported adverse reaction
LEUKOPENIA is the #19 most commonly reported adverse reaction for BASILIXIMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 366 FDA adverse event reports linking BASILIXIMAB to LEUKOPENIA. This represents approximately 1.6% of all 23,408 adverse event reports for this drug.
Patients taking BASILIXIMAB who experience leukopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LEUKOPENIA is a less commonly reported adverse event for BASILIXIMAB, but still significant enough to appear in the safety profile.
In addition to leukopenia, the following adverse reactions have been reported for BASILIXIMAB:
The following drugs have also been linked to leukopenia in FDA adverse event reports:
LEUKOPENIA has been reported as an adverse event in 366 FDA reports for BASILIXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
LEUKOPENIA accounts for approximately 1.6% of all adverse event reports for BASILIXIMAB, making it a notable side effect.
If you experience leukopenia while taking BASILIXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.